EMD Insider Trading

Insider Ownership Percentage: 30.21%
Insider Buying (Last 12 Months): A$1,873.21
Insider Selling (Last 12 Months): A$0.00

Emyria Insider Trading History Chart

This chart shows the insider buying and selling history at Emyria by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Emyria Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for EMD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Emyria Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/4/2025Michael WinloInsiderBuy69,378A$0.03A$1,873.21
8/8/2023Michael WinloInsiderBuy200,000A$0.10A$19,200.00
4/19/2022Michael WinloInsiderBuy60,000A$0.32A$19,080.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Emyria (ASX:EMD)

5.81% of Emyria stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Emyria logo
Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson's disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is under preclinical trial program; and provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the advancement of Emyria's MDMA analogue drug development program, targeting mental health and neurodegenerative diseases, including Parkinson's. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.
Read More on Emyria

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

471,333 shs

Average Volume

N/A

Market Capitalization

$16.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Who are the company insiders with the largest holdings of Emyria?

Emyria's top insider shareholders include:
  1. Michael Winlo (Insider)
Learn More about top insider investors at Emyria.